Pharmacokinetics and Pharmacodynamics of an Anti-HIV Drug in Israeli Ethiopian and Non-Ethiopian Populations

• Status: Withdrawn
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this proposal is based on the assumption that the HIV infected Ethiopian population responded in a different way in comparison to the Caucasian subjects to Lopinavir therapy. Our preliminary data demonstrated that Ethiopian's have different Lopinavir serum concentration in comparison to non-Ethiopian's. For these reasons the plan of this study is to investigate the pharmacokinetic/pharmacodynamic (PK/PD) profile in both populations. The results will allow to establish a better personalised medicine for HIV infected individuals.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rambam Health Care Campus
• Collaborator: Ministry of Health, Israel
• Treatments: Anti-HIV Agents; Lopinavir

Criteria

Inclusion Criteria:

• All HIV infected Ethiopian and Non-Ethiopian subjects

• AIDS diseased Ethiopian and Non-Ethiopian individuals

Exclusion Criteria:

• Individuals who are unable to sign the informed concent

• Individuals unable to take oral medications

• Individuals who described Lopinavir allergy